Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Liposomal Mitoxantrone in R/R NKTCL
NCT05464433Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University. Primary endpoints: Dose limited toxicities, Recommended Phase II Dose and 1 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
tislelizumabmitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT05464433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464433.